dr. levy on treatments for oncogenic-driven nsclc
Published 4 years ago • 380 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:34
dr. levy on entrectinib in oncogene-driven nsclc
-
1:09
dr. levy on first-line treatment for nondriver nsclc
-
1:02
dr. levy discusses the outlook for oncogene-driven nsclc
-
1:16
dr. levy on positive and negative biomarkers for immunotherapy in lung cancer
-
1:50
dr. levy on therapy for rapidly progressing nsclc
-
2:04
dr. levy on biomarkers of response to immunotherapy
-
1:14
dr. levy on investigational biomarkers of response to immunotherapy in nsclc
-
0:58
dr. shum on mechanisms of resistance in oncogene-driven nsclc
-
1:38:46
what you need to know about medical linacs - part 1
-
6:49
thomas levy - closing remarks
-
6:42
treatment of non-small cell lung cancer | best oncologist in kolkata
-
1:50
dr. levy discusses pembrolizumab in nsclc
-
1:59
dr. levy on the role of chemotherapy in the treatment of lung cancer
-
1:10
dr. levy on molecular drivers in nsclc
-
1:13
dr. levy on emerging biomarkers and corresponding therapies in lung cancer
-
0:55
dr. levy on the treatment of t790m-mutant lung cancer
-
2:03
dr. levy on the efficacy of crizotinib versus entrectinib in ros1 lung cancer
-
7:31
current management of oncogene-driven nsclc
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
1:04
dr. levy on egfr tkis in lung cancer
-
1:30
dr. levy on ongoing research evaluating the use of liquid biopsies in lung cancer
-
1:22
dr. levy on the benefits of liquid biopsies in nsclc